Martins-Branco, Diogo http://orcid.org/0000-0002-7214-4818
Nader-Marta, Guilherme http://orcid.org/0000-0001-7864-3637
Tecic Vuger, Ana http://orcid.org/0000-0003-2203-161X
Debien, Veronique http://orcid.org/0000-0003-1165-925X
Ameye, Lieveke http://orcid.org/0000-0001-5153-1766
Brandão, Mariana http://orcid.org/0000-0002-1653-3544
Punie, Kevin http://orcid.org/0000-0002-1162-7963
Loizidou, Angela http://orcid.org/0000-0002-2296-9264
Willard-Gallo, Karen http://orcid.org/0000-0002-1150-1295
Spilleboudt, Chloe http://orcid.org/0000-0002-8009-403X
Awada, Ahmad http://orcid.org/0000-0001-7412-9163
Piccart, Martine http://orcid.org/0000-0001-9068-8504
de Azambuja, Evandro http://orcid.org/0000-0001-9501-4509
Article History
Received: 15 June 2022
Accepted: 2 July 2022
First Online: 22 July 2022
Declarations
:
: DMB: Honoraria and advisory board fees from Daiichi Sankyo, Janssen, Pfizer, Merck Sharp and Dohme, Angelini, AstraZeneca, and Novartis, meeting/travel grants from LEO Farmacêuticos, Merck Sharp and Dohme, Ipsen, Janssen, Roche, Laboratórios Vitória, and Novartis, and institutional research grant from F. Hoffmann-La Roche Ltd (all outside the submitted work); GNM: Support to attend medical conferences: Roche and Bayer (all outside the submitted work); ATV: Honoraria and advisory board fees from Roche, Pfizer, Novartis, Astellas, meeting/travel grants from Roche, Pfizer, Novartis (all outside the submitted work); MB: Meeting/travel grants from Roche/GNE, Sanofi and Takeda; speaker fees from Roche/GNE and Jansen (all outside the submitted work); KP: KP’s institution received speaker fees, honoraria for advisory/consultancy roles and/or research funding from AstraZeneca, Eli Lilly, Gilead Sciences, Medscape, MSD, Mundi Pharma, Novartis, Pfizer, Pierre Fabre, Hoffmann/La Roche, Sanofi, Teva, Vifor Pharma. KP received travel support from AstraZeneca, Novartis, Pfizer, PharmaMar, Hoffmann/La Roche. K.P. received speaker fees and honoraria for advisory/consultancy roles from AstraZeneca, Gilead Sciences, Novartis, Roche, Seatlle Genetics (all outside the submitted work); KWG: Speaker fees, honoraria for advisory/consultancy roles and/or research funding from BMS, Pfizer, Philips and iTeos Therapeutics (all outside the submitted work); AA: Roche, Lilly, Amgen, EISAI, BMS, Pfizer, Novartis, MSD, Genomic Health, Ipsen, AstraZeneca, Bayer, Leo Pharma, Merck, Daiichi, Seattle Genetics, Pierre Fabre (all outside the submitted work); MP: Board Member (Scientific Board) from Oncolytics, consultant (honoraria) from AstraZeneca, Camel-IDS/Precirix, Gilead, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Pfizer, Roche-Genentech, Seattle Genetics, Immutep, Seagen, NBE Therapeutics, and Frame Therapeutics, and institutional research grants from AstraZeneca, Immunomedics, Lilly, Menarini, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, and Synthon (all outside the submitted work); EdA: Honoraria and/or advisory board from Roche/GNE, Novartis, Seattle Genetics, Zodiac, Libbs and Pierre Fabre. Travel grants from Roche/GNE and GSK/Novartis. Research grant to my institution from Roche/GNE, Astra-Zeneca, GSK/Novartis and Servier (all outside the submitted work). VD, LA, AL, and CS have no conflicts of interest to declare.
Free to read: This content has been made available to all.